Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ: WGS )

77.74 -3.95 (-4.84%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about GeneDx Holdings Corp. - Class A Common Stock

< Previous 1 2 Next >
GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
From GeneDx
Via Business Wire
Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening
From GeneDx
Via Business Wire
GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns
From GeneDx
Via Business Wire
GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
From GeneDx
Via Business Wire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx
Via Business Wire
GeneDx to Participate in Fall Investor Conferences
From GeneDx
Via Business Wire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx
Via Business Wire
GeneDx Announces Whole Genome Sequencing (WGS) Product Enhancements to Accelerate Diagnoses for More Patients
From GeneDx
Via Business Wire
GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights
From GeneDx
Via Business Wire
GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Participate in Upcoming Investor Conferences
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports First Quarter 2024 Financial Results and Business Highlights
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
The Company will also participate in a World Orphan Drug Congress panel presentation highlighting the role of genomic sequencing in advancing precision medicine 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Participate in 44th Annual Cowen Health Care Conference
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Preliminary 2023 Financial Results
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy
New research from one of the largest exome sequencing studies of patients with epilepsy adds to the mounting evidence that exome sequencing offers superior clinical results compared to multi-gene... 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Evolution of Executive Leadership Team
Melanie Duquette joining team as Chief Growth Officer to drive commercial excellence, Jennifer Brendel to take new role as Chief of Corporate Affairs amplifying the GeneDx brand and leadership... 
From GeneDx Holdings Corp.
Via GlobeNewswire
GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced
From GeneDx Holdings Corp.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.